Telmisartan Actavis (Telmisartan) 20 mg
Angiotensin II Receptor Blocker (ARB) for Hypertension & Cardiovascular Prevention
Telmisartan Actavis is a generic prescription medicine containing the active ingredient telmisartan, an angiotensin II receptor blocker (ARB). It is approved for the treatment of high blood pressure (essential hypertension) in adults and for the prevention of cardiovascular events in adults aged 55 years or older with established atherosclerotic disease or type 2 diabetes with documented end-organ damage. Telmisartan has the longest half-life of any ARB currently on the market (approximately 24 hours), providing smooth and sustained 24-hour blood pressure control with a single daily dose. The 20 mg tablet strength is typically used as a starting dose for patients who need a gentle initiation, including the elderly and those with volume depletion or hepatic impairment. Telmisartan is also sold under brand names including Micardis, Pritor, and Kinzalmono.
Quick Facts
Key Takeaways
- Telmisartan Actavis is a generic angiotensin II receptor blocker (ARB) that lowers blood pressure by relaxing blood vessels and reducing the workload on the heart.
- In addition to treating hypertension, telmisartan is approved for cardiovascular prevention in high-risk adults aged 55 or older, based on the landmark ONTARGET trial.
- Telmisartan has the longest half-life of all ARBs (~24 hours), providing smooth 24-hour blood pressure control and covering the early morning blood pressure surge.
- Telmisartan Actavis must not be used during pregnancy, in combination with aliskiren in diabetic or renally impaired patients, or together with ACE inhibitors (dual RAAS blockade).
- Common side effects include dizziness, low blood pressure, upper respiratory or urinary tract infections; the medicine is generally well tolerated and rarely causes the dry cough associated with ACE inhibitors.
What Is Telmisartan Actavis and What Is It Used For?
Telmisartan Actavis belongs to a class of medicines called angiotensin II receptor antagonists, commonly known as ARBs or sartans. Angiotensin II is a potent endogenous vasoconstrictor produced by the renin-angiotensin-aldosterone system (RAAS). When angiotensin II binds to AT1 receptors on the smooth muscle of blood vessels, it triggers vasoconstriction, stimulates aldosterone release, and promotes sodium and water retention. These combined actions raise blood pressure and increase the workload of the heart. Telmisartan selectively and insurmountably blocks the AT1 receptor, preventing these effects and causing blood vessels to dilate, blood pressure to fall, and fluid balance to normalize.
Among all ARBs, telmisartan has a uniquely long elimination half-life of approximately 24 hours, which is roughly twice that of losartan or irbesartan. This pharmacokinetic advantage translates into smoother, more consistent blood pressure control across the entire 24-hour dosing interval, particularly during the last few hours before the next dose and during the early morning period, when blood pressure typically surges and cardiovascular events such as stroke and myocardial infarction are most frequent. The medication also has high lipophilicity and a large volume of distribution, allowing for deep tissue penetration.
The first approved indication for Telmisartan Actavis is the treatment of essential hypertension in adults. Hypertension is one of the most common chronic conditions worldwide, affecting approximately 1.28 billion adults according to the World Health Organization. Persistently elevated blood pressure damages the inner lining of arteries, accelerates atherosclerosis, and increases the risk of ischemic heart disease, heart failure, stroke, chronic kidney disease, and premature death. By effectively and safely lowering blood pressure, telmisartan helps reduce these risks and preserve organ function over time.
The second approved indication is cardiovascular prevention in high-risk patients, specifically adults aged 55 years and older with manifest atherothrombotic cardiovascular disease (a history of coronary artery disease, stroke, transient ischemic attack, peripheral arterial disease, or previous myocardial infarction) or type 2 diabetes mellitus with documented target-organ damage. This indication is based on the ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) study, which enrolled more than 25,000 patients and demonstrated that telmisartan 80 mg was non-inferior to ramipril 10 mg in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure.
In addition to blocking AT1 receptors, telmisartan also exhibits a partial agonist activity at the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor involved in glucose and lipid metabolism. Although the clinical relevance of this effect remains an area of investigation, it may contribute to modest improvements in insulin sensitivity, lipid profile, and endothelial function. This dual mechanism is considered unique among commercially available ARBs and has generated ongoing interest in telmisartan's potential metabolic and anti-inflammatory effects.
Telmisartan is rapidly absorbed following oral administration, with peak plasma concentrations reached within 30 minutes to 1 hour. Its oral bioavailability is dose-dependent (approximately 42% at the 40 mg dose and 58% at the 160 mg dose). The drug is almost entirely metabolized by glucuronide conjugation of the parent molecule, with negligible involvement of cytochrome P450 enzymes, minimizing the potential for CYP-mediated drug-drug interactions. Elimination occurs almost exclusively through biliary excretion in the feces, which makes dose adjustment generally unnecessary in patients with renal impairment.
What Should You Know Before Taking Telmisartan Actavis?
Before starting therapy with Telmisartan Actavis, it is important to have a thorough discussion with your healthcare provider about your medical history, current medications, and any other products you use (including over-the-counter medicines, dietary supplements, and herbal preparations). Several conditions may require dose adjustment, careful monitoring, or selection of a different medicine. This section summarizes the most important safety considerations.
Contraindications
There are specific circumstances in which Telmisartan Actavis should never be taken. Understanding these contraindications is essential for safe use of this medication:
- You are allergic (hypersensitive) to telmisartan or to any of the other ingredients in the tablet.
- You are more than three months pregnant. Telmisartan should also be avoided during early pregnancy whenever possible.
- You have severe liver disease, biliary obstruction, or severe cholestasis (since telmisartan is eliminated almost entirely through the biliary system).
- You have diabetes or moderate-to-severe renal impairment and are also taking a blood pressure-lowering medicine containing aliskiren.
Warnings and Precautions
Several conditions and situations require special caution, closer monitoring, or individualized dose selection during treatment with telmisartan. Your physician will weigh the benefits and risks based on your personal health status.
Patients with renovascular hypertension (narrowing of the renal artery, either bilaterally or in a single functioning kidney) may experience a significant fall in blood pressure and a deterioration of kidney function when starting telmisartan. Renin-angiotensin system inhibition removes a compensatory mechanism that maintains glomerular filtration rate in such patients, so treatment should only be initiated under close medical supervision with serial measurements of serum creatinine, urea, and potassium.
Patients with kidney impairment should be monitored carefully during treatment. Telmisartan can cause reversible increases in blood urea nitrogen (BUN) and serum creatinine, particularly in volume-depleted patients or those with baseline renal dysfunction. In patients with severe renal impairment or those undergoing dialysis, lower starting doses are recommended and regular laboratory monitoring (creatinine, electrolytes) is essential.
In patients with liver impairment or biliary obstructive disorders, plasma concentrations of telmisartan may be increased because of reduced hepatobiliary clearance. Telmisartan should be used with caution in patients with mild to moderate hepatic impairment and must not be used in those with severe hepatic disease. A starting dose of 20 mg once daily is particularly appropriate in this setting, which is one of the reasons the 20 mg strength of Telmisartan Actavis is clinically valuable.
Patients with volume and/or sodium depletion — for example, those receiving high-dose diuretic therapy, patients on a salt-restricted diet, or individuals with persistent vomiting or diarrhea — are at increased risk of symptomatic hypotension (low blood pressure) after the first dose of telmisartan. These conditions should ideally be corrected before starting therapy, or treatment should be initiated at the lowest available dose (20 mg) with close monitoring of blood pressure.
Patients whose vascular tone and renal function depend heavily on the renin-angiotensin system — including those with severe congestive heart failure or underlying renal disease including renal artery stenosis — may experience acute hypotension, azotemia, or acute kidney injury when ARBs are introduced. Careful dose titration and frequent monitoring are necessary in such patients.
Hyperkalemia (high blood potassium levels) can develop during ARB therapy, particularly in patients with renal insufficiency, diabetes mellitus, heart failure, or those taking potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other drugs that increase potassium (such as heparin). Serum potassium should be monitored regularly during treatment with telmisartan.
Patients with primary aldosteronism generally do not respond adequately to antihypertensive drugs that act by inhibiting the renin-angiotensin system. Use of telmisartan in these patients is not recommended.
In patients undergoing surgery or anesthesia, ARBs may enhance the hypotensive effects of anesthetic agents. Inform your surgical team well in advance that you are taking telmisartan so they can decide whether to continue, adjust, or temporarily pause treatment before the procedure.
Your doctor should periodically monitor your blood pressure, kidney function (serum creatinine and estimated glomerular filtration rate), and electrolyte levels (particularly potassium and sodium) throughout treatment with Telmisartan Actavis. Do not stop taking this medicine on your own, even if you feel well — high blood pressure often causes no symptoms until a serious event occurs.
Dual Blockade of the Renin-Angiotensin System
Concomitant use of Telmisartan Actavis with ACE inhibitors (such as enalapril, lisinopril, or ramipril) or with the direct renin inhibitor aliskiren is generally not recommended. The ONTARGET trial demonstrated that combining telmisartan with ramipril did not confer additional cardiovascular benefit but was associated with a significant increase in adverse events, including hypotension, syncope, hyperkalemia, and acute kidney injury. In patients with diabetes or moderate-to-severe renal impairment, the combination of telmisartan with aliskiren is strictly contraindicated. When dual RAAS blockade is considered absolutely necessary (for example, in some specialist-managed cases of proteinuric kidney disease), it must be performed under close specialist supervision with strict monitoring of blood pressure, kidney function, and electrolytes.
Pregnancy and Breastfeeding
Pregnancy: Telmisartan Actavis is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters. Exposure to ARBs during the second and third trimesters is associated with fetal toxicity, including hypotension, renal failure, oligohydramnios (low amniotic fluid), delayed skull ossification, pulmonary hypoplasia, and limb contractures, and has been linked to neonatal death. If pregnancy is detected during treatment, telmisartan should be stopped immediately and an alternative antihypertensive with an established safety profile in pregnancy should be started. Women of childbearing potential should discuss contraception and pregnancy planning with their physician before starting treatment.
Breastfeeding: Because no data are available regarding the use of telmisartan during breastfeeding, it is not recommended for mothers who are breastfeeding. Alternative antihypertensive treatments with better-established safety profiles during lactation should be preferred, particularly when nursing a newborn or a premature infant.
Children and Adolescents
The safety and efficacy of Telmisartan Actavis in children and adolescents under 18 years of age have not been established. The medicine should therefore not be used in this age group outside of specialized pediatric cardiology or nephrology settings. If a child accidentally swallows any tablets, contact a poison control center or emergency department immediately.
Driving and Using Machines
Telmisartan Actavis is unlikely to impair the ability to drive or operate machinery in most patients. However, dizziness, fatigue, or occasional fainting (syncope) may occur, particularly at the start of treatment, after a dose increase, or when the medicine is combined with a diuretic. If you experience such symptoms, avoid driving or operating machinery until they resolve.
Information About Ingredients
Telmisartan Actavis tablets may contain sorbitol. Patients with hereditary fructose intolerance should not take this medicine. If your doctor has told you that you have an intolerance to certain sugars, contact your doctor before taking Telmisartan Actavis. The tablets are also essentially sodium-free (less than 1 mmol, or 23 mg, of sodium per tablet), which is advantageous for patients on a low-sodium diet.
How Does Telmisartan Actavis Interact with Other Drugs?
Drug interactions can alter how telmisartan works in your body and may increase the risk of side effects. It is essential to provide your healthcare provider with a complete list of all the prescription drugs, over-the-counter medicines, vitamins, mineral supplements, and herbal products you are currently using. Below are the most clinically important interactions to be aware of.
Major Interactions
The following interactions are clinically significant and may require dose adjustment, additional laboratory monitoring, or avoidance of the combination altogether:
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| ACE inhibitors (ramipril, enalapril, lisinopril, perindopril) | Dual RAAS blockade increases risk of hypotension, hyperkalemia, and acute kidney injury without added cardiovascular benefit (ONTARGET evidence). | Avoid the combination. If dual therapy is unavoidable, use only under strict specialist supervision. |
| Aliskiren | Increased risk of hypotension, hyperkalemia, and renal impairment. | Contraindicated in patients with diabetes or moderate-to-severe renal impairment; avoid in all other patients when possible. |
| Potassium supplements, potassium-containing salt substitutes | Dangerously elevated serum potassium (hyperkalemia), risk of cardiac arrhythmia. | Avoid routine use; monitor serum potassium regularly if combination is unavoidable. |
| Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Additive risk of hyperkalemia, especially in patients with impaired kidney function or heart failure. | Use only with close monitoring of potassium and creatinine. |
| Lithium | Reversible increases in serum lithium levels; risk of lithium toxicity (tremor, confusion, seizures). | Monitor lithium levels closely; dose adjustment is often required. |
| Digoxin | Mean peak and trough digoxin concentrations may rise by about 49% and 20%, respectively. | Monitor digoxin levels regularly at initiation, dose adjustment, and discontinuation of telmisartan. |
Minor or Moderate Interactions
The following interactions are less severe but may still affect therapy and should be reviewed with your doctor or pharmacist:
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, acetylsalicylic acid >3 g/day, COX-2 inhibitors) | May reduce the antihypertensive effect of telmisartan and increase the risk of acute kidney injury, especially in dehydrated or elderly patients. | Use the lowest effective NSAID dose for the shortest duration; ensure adequate hydration; monitor blood pressure and kidney function. |
| Other antihypertensive agents (diuretics, calcium channel blockers, beta-blockers) | Additive blood pressure-lowering effect, which is usually desired but may cause hypotension. | Monitor blood pressure closely, particularly after dose changes. |
| Corticosteroids (prednisolone, methylprednisolone) and ACTH | May reduce the antihypertensive effect of telmisartan through fluid and sodium retention. | Monitor blood pressure; adjust doses of antihypertensive therapy if needed. |
| Insulin and oral antidiabetic agents | May enhance glucose-lowering effect; potential for hypoglycemia, particularly in early treatment. | Monitor blood glucose; adjust diabetes medication doses as appropriate. |
| Tricyclic antidepressants, antipsychotics, baclofen, amifostine | Additive hypotensive effect, increased risk of orthostatic hypotension. | Use with caution; advise the patient to rise slowly from sitting or lying positions. |
Telmisartan Actavis can be taken with or without food. Food may slightly decrease systemic absorption, but this is not clinically relevant. Avoid excessive consumption of potassium-rich foods (bananas, oranges, potatoes, spinach) and potassium-based salt substitutes if your doctor has told you that your potassium levels are high or that your kidney function is reduced. Limit alcohol intake, as alcohol can further lower blood pressure and cause dizziness.
What Is the Correct Dosage of Telmisartan Actavis?
Always take Telmisartan Actavis exactly as your doctor has prescribed. If you are unsure about your dose, check with your physician or pharmacist. Telmisartan tablets are taken by mouth (orally), swallowed whole with a full glass of water. They can be taken with or without food. Try to take your daily dose at approximately the same time each day to help you remember and to maintain stable blood levels.
Adults
Essential Hypertension
The usual recommended starting dose is 40 mg once daily. Some patients may benefit from a lower starting dose of 20 mg once daily, particularly those who are elderly, volume-depleted, or who have hepatic impairment. If the target blood pressure is not achieved, the dose can be increased to a maximum of 80 mg once daily. The full antihypertensive effect is typically reached after four to eight weeks of continuous treatment. Telmisartan may also be combined with other antihypertensive medications (for example, thiazide diuretics or calcium channel blockers) if a single agent is insufficient.
Cardiovascular Prevention (High-Risk Adults ≥ 55 Years)
The recommended dose for cardiovascular event prevention is 80 mg once daily. Treatment is intended for long-term use and should be started under medical supervision, with gradual titration from 40 mg to 80 mg if tolerated. During initial treatment, close monitoring of blood pressure and kidney function is advised. Occasional adjustment of concomitant antihypertensive therapy may be necessary to avoid excessive blood pressure reduction.
Patients With Renal Impairment
Telmisartan is almost entirely eliminated through biliary excretion, so no dose adjustment is generally required based on kidney function alone. However, in patients with severe renal impairment (creatinine clearance < 30 mL/min) or those on hemodialysis, a lower starting dose of 20 mg once daily is recommended, and kidney function and potassium should be monitored carefully. Telmisartan is not removed by hemodialysis.
Patients With Hepatic Impairment
In patients with mild to moderate hepatic impairment, the daily dose should not exceed 40 mg once daily. In patients with severe hepatic impairment or cholestatic disorders, telmisartan is contraindicated. The 20 mg strength is particularly useful for initiating therapy in patients with liver disease.
Children
Telmisartan Actavis should not be given to children or adolescents under 18 years of age, as the safety and efficacy of telmisartan have not been established in this age group. Accidental ingestion by a child should be treated as a medical emergency — contact a poison control center or seek immediate medical attention.
Elderly
No dose adjustment is required solely on the basis of age. However, elderly patients (particularly those aged 75 and over) are more sensitive to blood-pressure-lowering effects and may benefit from starting at the 20 mg once daily dose with gradual uptitration as tolerated. Blood pressure should be checked regularly during the initial weeks.
Missed Dose
If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next scheduled dose, skip the missed dose and continue with your usual schedule. Do not take a double dose to make up for a forgotten one. Consistent daily dosing is important for reliable blood pressure control, since ARBs rely on steady plasma levels for optimal effect.
Overdose
If you or someone else has taken more Telmisartan Actavis tablets than prescribed, contact a doctor, poison control center, or emergency department immediately. The most prominent signs of telmisartan overdose are severely low blood pressure (hypotension) with dizziness, fainting, and tachycardia (fast heartbeat); bradycardia (slow heartbeat) may also occur. Acute kidney injury and electrolyte disturbances are possible. Treatment is symptomatic and supportive (intravenous fluids, vasopressors if needed). Telmisartan is not removed by hemodialysis.
What Are the Side Effects of Telmisartan Actavis?
Like all medicines, Telmisartan Actavis can cause side effects, although not everybody gets them. Most side effects are mild to moderate and often improve as the body adjusts to treatment. A small number of side effects, however, can be serious and require prompt medical attention. The frequency of adverse events listed below is based on the European Medicines Agency Summary of Product Characteristics and post-marketing surveillance data.
Sudden swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; hives or a severe skin rash; sudden severe dizziness or fainting; signs of severe infection (high fever, persistent sore throat, unexplained bruising or bleeding); or signs of reduced urine output or dark brown urine. Stop taking Telmisartan Actavis and call emergency services or go to the nearest emergency department. These symptoms may indicate a life-threatening allergic reaction (angioedema), sepsis, or severe kidney injury.
Common
May affect up to 1 in 10 patients
- Upper respiratory tract infections, sinusitis, sore throat
- Urinary tract infections (including cystitis)
- Dizziness
- Low blood pressure (hypotension), especially orthostatic (on standing)
- High potassium levels (hyperkalemia) in the blood
- Diabetes mellitus (in high-risk patients)
Uncommon
May affect up to 1 in 100 patients
- Anemia
- Anxiety, depression, insomnia
- Fainting (syncope)
- Blurred vision
- Vertigo, tinnitus
- Slow heartbeat (bradycardia), palpitations
- Shortness of breath, cough
- Abdominal pain, diarrhea, flatulence, dyspepsia, vomiting
- Itching (pruritus), rash, hyperhidrosis (sweating)
- Muscle pain (myalgia), back pain, muscle cramps
- Kidney impairment, acute kidney failure
- Chest pain, fatigue, asthenia
- Increased creatinine levels
Rare
May affect up to 1 in 1,000 patients
- Sepsis (including fatal outcomes) — reported during post-marketing observation
- Thrombocytopenia (low platelet count), eosinophilia
- Angioedema (including fatal outcome)
- Drug eruption, urticaria
- Tendon pain or inflammation (tendinopathy-like symptoms)
- Abnormal liver function, hepatic disorder (most reported cases occurred in Japanese patients)
- Increased uric acid
- Flu-like syndrome
Not Known
Frequency cannot be estimated from available data (post-marketing reports)
- Progressive fibrosis of the lungs (interstitial lung disease)
- Hypoglycemia (in diabetic patients)
- Severe cutaneous adverse reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome — very rare)
- Rhabdomyolysis (muscle breakdown) in isolated cases
- Decreased hemoglobin
If you experience any side effects, even those not listed in the package leaflet or above, please talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority (for example, the U.S. Food and Drug Administration's MedWatch program, the UK Medicines and Healthcare products Regulatory Agency Yellow Card Scheme, or the European Medicines Agency). Voluntary reporting helps regulators and healthcare professionals improve the safe use of medicines.
How Should You Store Telmisartan Actavis?
Proper storage ensures that your medicine remains safe and effective throughout its labeled shelf life. Follow these guidelines for Telmisartan Actavis:
- Temperature: Store at temperatures below 30 °C (86 °F). Do not freeze.
- Packaging: Keep the tablets in the original blister pack to protect them from moisture. Remove a tablet from the blister only immediately before you take it.
- Children: Keep this medicine out of the sight and reach of children and pets at all times. Even a small number of tablets can cause serious blood pressure drops in small children.
- Expiry date: Do not use Telmisartan Actavis after the expiry date (EXP) stated on the carton and blister. The expiry date refers to the last day of the specified month.
- Disposal: Do not throw away unused tablets in household waste or wastewater. Return expired or unused medicine to your pharmacy for safe disposal. This helps protect the environment and prevents accidental exposure.
What Does Telmisartan Actavis Contain?
Each Telmisartan Actavis tablet contains a specified amount of the active ingredient telmisartan along with inactive ingredients (excipients) that give the tablet its form, stability, and shelf life.
Active Substance
The active substance is telmisartan. Each Telmisartan Actavis 20 mg tablet contains 20 milligrams of telmisartan. Other strengths (40 mg and 80 mg) may be available separately and are used depending on clinical needs.
Other Ingredients (Excipients)
The tablet core typically contains: sorbitol (E420), meglumine, povidone, sodium hydroxide, and magnesium stearate. Generic telmisartan formulations may vary slightly between manufacturers, so patients with known excipient allergies should always verify the full ingredient list on the package leaflet supplied with their specific product.
Appearance and Pack Sizes
Telmisartan Actavis 20 mg tablets are typically white to off-white, round or oval tablets, supplied in aluminum-aluminum blister packs in pack sizes of 14, 28, 30, 56, 84, 90, or 98 tablets. Not all pack sizes may be marketed in every country. The exact appearance (imprint, shape) may vary slightly depending on the manufacturing site.
Marketing Authorization Holder and Manufacturer
Telmisartan Actavis is marketed by Actavis Group PTC ehf. (part of Teva Pharmaceuticals) in several European countries. The specific manufacturer and packaging site are listed in the package leaflet accompanying each pack.
Frequently Asked Questions About Telmisartan Actavis
Telmisartan Actavis is used to treat essential hypertension (high blood pressure) in adults. It is also approved for cardiovascular prevention in adults aged 55 years or older who have atherosclerotic cardiovascular disease (such as a history of coronary artery disease, stroke, or peripheral arterial disease) or type 2 diabetes with documented target-organ damage. By blocking the angiotensin II receptor, telmisartan relaxes the blood vessels, lowers blood pressure, and reduces strain on the heart.
No. Telmisartan Actavis must not be used during the second and third trimesters of pregnancy, and its use during the first trimester is not recommended. It can cause serious harm to the developing baby, including kidney damage, reduced amniotic fluid, skull malformations, and even fetal or neonatal death. If you suspect you are pregnant or become pregnant during treatment, contact your doctor immediately so they can change you to a safer antihypertensive medication.
Telmisartan begins lowering blood pressure within three hours of the first dose. The full antihypertensive effect is generally reached after four to eight weeks of continuous therapy. Because telmisartan has a half-life of about 24 hours — the longest of all ARBs — blood pressure is controlled smoothly throughout the whole day and night, including the critical early morning surge when cardiovascular events are most common.
Common side effects (affecting up to 1 in 10 patients) include upper respiratory tract infections, sinusitis, urinary tract infections, dizziness, low blood pressure (especially on standing), and increased blood potassium levels. Most are mild and improve over time. Unlike ACE inhibitors, telmisartan rarely causes persistent dry cough. If side effects are severe or persistent, talk to your doctor before stopping the medicine.
Yes, telmisartan is commonly combined with other antihypertensive drug classes, such as thiazide diuretics (for example, hydrochlorothiazide), calcium channel blockers (for example, amlodipine), or beta-blockers, under medical supervision. However, it should not be combined with ACE inhibitors (such as ramipril, enalapril, or lisinopril) or with aliskiren, especially in patients with diabetes or kidney impairment. This dual blockade of the renin-angiotensin system increases the risk of dangerously low blood pressure, high potassium, and acute kidney injury without offering additional benefit.
If you miss a dose, take it as soon as you remember the same day. If it is almost time for your next scheduled dose, skip the missed one and continue with your usual schedule — do not take a double dose to compensate. To minimize missed doses, consider taking your medicine at the same time every day and using a daily pill organizer or a smartphone reminder.
A persistent dry cough is a well-known side effect of ACE inhibitors (such as ramipril or lisinopril) but occurs much less frequently with ARBs like telmisartan. This is because ARBs do not affect the breakdown of bradykinin, the peptide believed to mediate ACE inhibitor-induced cough. Patients who develop cough on an ACE inhibitor are often switched to an ARB such as telmisartan and typically experience resolution of cough while maintaining blood pressure control.
Telmisartan is eliminated almost entirely through biliary excretion in the feces, so no dose adjustment is generally needed based on kidney function alone. It can even be beneficial in patients with proteinuric kidney disease because ARBs reduce intraglomerular pressure and proteinuria. However, in patients with severe renal impairment or those on hemodialysis, a lower starting dose of 20 mg once daily is recommended, with regular monitoring of serum creatinine and potassium. Telmisartan must not be combined with aliskiren in patients with moderate-to-severe kidney impairment.
References
This article is based on approved prescribing information, international clinical guidelines, and peer-reviewed medical literature. All sources are independent and free from commercial influence.
- European Medicines Agency (EMA). Micardis (telmisartan) — Summary of Product Characteristics and European Public Assessment Report. EMA Micardis EPAR. Last updated 2026.
- U.S. Food and Drug Administration (FDA). MICARDIS (telmisartan) tablets prescribing information. Silver Spring, MD: FDA. FDA Label (accessdata.fda.gov).
- Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). WHO Essential Medicines.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2022. NICE NG136.
- British National Formulary (BNF). Telmisartan — indications, dose, contraindications, side-effects. BNF Telmisartan.
- Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (ONTARGET). The Lancet. 2008;372(9638):547–553. doi:10.1016/S0140-6736(08)61236-2
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension. 2004;43(5):993–1002. doi:10.1161/01.HYP.0000123072.34629.57
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specializing in cardiology, internal medicine, nephrology, and clinical pharmacology.
Medical Content Team
Specialists in cardiovascular medicine, nephrology, and clinical pharmacology with documented academic backgrounds and clinical experience in the management of hypertension and cardiovascular risk reduction.
Medical Review Board
Independent panel of board-certified physicians who review all medication content according to international guidelines (ESC/ESH, AHA/ACC, NICE, WHO) and the GRADE evidence framework.
Editorial Standards: All content follows our editorial standards and is based on peer-reviewed research, international clinical guidelines, and approved prescribing information. We maintain complete editorial independence with no pharmaceutical sponsorship or advertising.
Last Medical Review: | Content Version: 1.0